(Reuters) – GlaxoSmithKline Plc said some bottles of its weight-loss drug Alli bought in the United States had been tampered with and that the U.S. Food and Drug Administration was investigating. Consumers reported that some bottles bought in stores in seven states contained products other than the drug, the company said on Wednesday. The bottles also could be unlabeled and the lot numbers might not match the numbers on the carton, it said. The company did not say if any consumers had taken pills from the bottles or if it was considering a recall.